Figure 2

Uncanonical pEBNA3A presentation by HLA-B*2705 in a second B*2705/B*07-positive AS patient. (A) Measurement of IFNγ secretion in PBMCs from Don 2.05.07 stimulated with pEBNA3A for 14 d and then re-stimulated by untreated or pEBNA3A-pulsed C1R transfectants. Numbers represent the percentage of IFNγ-producing CD8⁺ T cells. (B) Schematic representation of the pEBNA3A-chimeric protein showing the location at the N-terminus of 6-His tag, the TAT transduction domain and the hemoagglutinin (HA) tag followed by the nucleoprotein of influenza A virus protein in which the sequence of EBNA3A epitope has been inserted. (C) ⁵¹Cr-release assay in which cytolytic effector functions of a representative pEBNA3A-stimulated CTL line was tested against C1R transfected cells, pre-pulsed with pEBNA3A provided as synthetic peptide (30 µmol/L) or transduced by the chimeric protein carrying EBNA3A epitope (1 µmol/L). E/T ratio was 20:1. Bars represent the mean percentage of specific lysis ± SEM of three separate experiments.